🔬 Now at Pharmidex: The 8HUM Model
July 21, 2025
Pharmidex is proud to offer access to the 8HUM model genetically humanized for 33 liver CYP enzymes responsible for metabolizing 90% of human drugs.
✅ Human-relevant metabolism data
✅ Supports IND-enabling & regulatory studies
✅ Ideal for metabolite profiling, DDI risk & toxicity assessment
By integrating 8HUM into our DMPK and in vivo studies, we deliver deeper, more predictive insights for safer, smarter drug development.
📩 Contact us to see how 8HUM can support your project.
#Pharmidex #8HUM #DrugMetabolism #DMPK #PreclinicalResearch #InVivoPharmacology #DrugDevelopment
Head of Respiratory at Pharmidex , Ian Knowles will be attending the Drug Delivery to the Lungs Conference (DDL) on 10–12 December 2025 at the Edinburgh International Conference Centre. DDL brings together global leaders in pulmonary and respiratory drug delivery, and Ian looks forward to meeting fellow attendees, exploring collaborations, and discussing how Pharmidex can support and accelerate drug discovery and development across industry and academia. If you’ll be there too, feel free to reach out we look forward to building new connections and advancing innovation together.
Pharmidex is pleased to announce that Dr. Mo Alavijeh (FRSC, FRSM) and Janette Dalay Robertson will attend the “Recent Clinical Candidates and SMR Award Meeting” this Thursday, 4 December 2025. If you’re attending, we’d be happy to connect!
Pharmidex is pleased to announce that Dr. Mo Alavijeh (FRSC, FRSM) , and our Dr. Ian Knowles , will attend Genesis 2025 this Wednesday, December 3rd, hosted by One Nucleus . They look forward to meeting fellow attendees, exploring new collaborations, and building partnerships with companies and academic groups to advance drug discovery and development. See you at Genesis 2025!
